NOVARTIS logo.jpg
Novartis completes tender offer for all outstanding shares of The Medicines Company
January 06, 2020 01:00 ET | Novartis International AG
Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger...
NOVARTIS logo.jpg
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
December 16, 2019 01:15 ET | Novartis International AG
Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events balanced across treatment...
NOVARTIS logo.jpg
Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD
December 13, 2019 07:03 ET | Novartis International AG
In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1 In a pre-specified secondary endpoint, fewer patients had intra-retinal...
NOVARTIS logo.jpg
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
December 09, 2019 14:45 ET | Novartis International AG
Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3  Fewer known CAR-T cell therapy adverse...
NOVARTIS logo.jpg
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
December 06, 2019 01:15 ET | Novartis International AG
Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate1 QMF149 showed improvement in peak expiratory...
NOVARTIS logo.jpg
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day
December 05, 2019 01:15 ET | Novartis International AG
Uniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms60 projects in Phase 2 pipeline with 10+ advancing...
NOVARTIS logo.jpg
Novartis tender offer for The Medicines Company commences
December 05, 2019 01:00 ET | Novartis International AG
Basel, December 5, 2019 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation (“Purchaser”), has commenced...
TELUS launches breathtaking 4K HDR TV -- a first in Canada
April 19, 2018 08:00 ET | TELUS Communications Inc
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- TELUS has again raised the bar for TV in Canada with the launch of 4K HDR on Optik TV. Already the only TV provider in Western Canada...
TELUS launches Boost Wi-Fi to increase wireless internet speed and coverage at home
April 05, 2018 08:00 ET | TELUS Communications Inc
VANCOUVER, British Columbia, April 05, 2018 (GLOBE NEWSWIRE) -- TELUS announced the launch of Boost Wi-Fi, a powerful system that extends the reach of in-home Wi-Fi signals to ensure every corner of...
NOVARTIS logo.jpg
Entscheidung über zwei Neubauten im Novartis Campus
December 18, 2003 09:15 ET | Novartis Pharma AG
Entscheidung über zwei Neubauten im Novartis Campus gefallen   Basel, 18. Dezember 2003 - Nachdem im April bereits der Entscheid für das zweite Bürogebäude im Novartis Campus gefallen war, hat am...